Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) EPS (Weighted Average and Diluted) (2023 - 2025)

Mangoceuticals' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.01 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 98.08% to -$0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.56, a 43.49% increase, with the full-year FY2025 number at -$2.17, up 54.79% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.01 in Q4 2025 for Mangoceuticals, up from -$0.69 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for MGRX hit a ceiling of -$0.01 in Q4 2025 and a floor of -$1.9 in Q4 2023.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.92 across 3 years, with a median of -$0.91 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 878.57% in 2024 and later soared 98.08% in 2025.
  • Tracing MGRX's EPS (Weighted Average and Diluted) over 3 years: stood at -$1.9 in 2023, then soared by 72.63% to -$0.52 in 2024, then soared by 98.08% to -$0.01 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for MGRX at -$0.01 in Q4 2025, -$0.69 in Q3 2025, and -$0.57 in Q2 2025.